Inflammatory bowel diseases

risk factors and impact on quality of life

Authors

DOI:

https://doi.org/10.23925/1984-4840.2025v27a24

Keywords:

Crohn's Disease, Ulcerative Colitis, Risk Factors, Quality of Life

Abstract

Introduction: Inflammatory bowel diseases (IBD) are chronic conditions of multifactorial etiology that directly impact patients’ lives. Objectives: This study aimed to evaluate the impact on the quality of life of patients with Crohn’s disease (CD) and ulcerative colitis (UC), as well as to identify possible environmental risk factors associated with IBD. Methods: Twenty-seven patients of both sexes, previously diagnosed with CD or UC, participated in the study. Demographic, risk factor, and quality-of-life questionnaires (Inflammatory Bowel Disease Questionnaire, IBDQ-32) were administered. Results: The patients had a mean age of 34.8 ± 12.7 years. UC was the most prevalent disease (18 patients), and excessive antibiotic use was reported by 83.3% of patients with UC. Family history was cited by 11.1% of the sample. The IBDQ-32 revealed that patients with CD had lower scores than those with UC, with significant impact on the systemic and emotional domains. Furthermore, the greater the use of medication, the poorer the results in the IBDQ-32. Conclusions: This study highlights the high percentage of antibiotic use during childhood among patients with UC and underscores the impact of inflammatory diseases, particularly on the emotional domain, on patients’ quality of life.

Downloads

Download data is not yet available.

Author Biographies

Eduardo de Souza Andrade, Universidade do Planalto Catarinense (UNIPLAC)

Médico com mestrado em Ambiente e Saúde Universidade do Planalto Catarinense, residência média em Coloproctologia pelo Hospital Heliópolis de São Paulo - SP e Cirurgião Geral pelo Hospital São José de Criciúma - SC, membro da Sociedade Brasileira de Coloproctologia e da Sociedade Brasileira de Vídeocirurgia. Professor-Tutor do curso de graduação em Medicina da Universidade do Planalto Catarinense. Área da medicina com ênfase em Coloproctologia, Colonoscopia, Cirurgia geral e núcleo interno de regulação médica. Destaque para os seguintes temas: câncer colorretal, doenças inflamatórias intestinais, doença de crohn, retocolite ulcerativa, síndrome do intestino irritável, doenças orificiais e gestão hospitalar.

Caio Zimermann Oliveira, Universidade do Planalto Catarinense (UNIPLAC)

Médico pela Universidade do Planalto Catarinense. Realiza atividade médica ambulatorial e atendimento em pronto-socorro e unidades hospitalares para atendimento de emergência e urgências

Julia Melin Zardo, Universidade do Planalto Catarinense (UNIPLAC)

Graduanda no Curso de Medicina da Universidade do Planalto Catarinense

Vanessa Valgas dos Santos, Universidade do Planalto Catarinense (UNIPLAC)

Graduada em Farmácia Análises Clínicas pela Universidade Federal de Santa Catarina, possui Mestrado em Farmácia, tendo como área de concentração Imunologia e Microbiologia. O Doutorado em Neurociências foi desenvolvido no Departamento de Farmacologia na mesma instituição de ensino, sob orientação do Professor Dr. Rui Prediger, investigando o papel neuroprotetor dos hormônios orexígenos grelina e NPY no modelo experimental da doença de Alzheimer. A seguir, para desvendar os efeitos dos hormônios acil-grelina e desacil-grelina na neurodegeneração e na obesidade, investigar suas ações sobre o comportamento emocional e memória, foi para Monash University (Melbourne - Austrália) onde realizou seu pós-doutorado com o Professor Dr. Zane Andrews. Atualmente é professora do Programa de Pós-Graduação em Ambiente e Saúde da Universidade do Planalto Catarinense (UNIPLAC), professora de Farmacologia e Tutora do curso de Medicina, onde pesquisa os efeitos deletérios das doenças crônicas, seus fatores de risco, a obesidade e as consequências sistêmicas da cirurgia bariátrica.

References

Bruner LP, White AM, Proksell S. Inflammatory bowel disease. Prim Care. 2023;50(3):411-27. doi: 10.1016/j.pop.2023.03.009.

Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental risk factors for inflammatory bowel diseases: an umbrella review of meta-analyses. Gastroenterology. 2019;157(3):647-59.e4. doi: 10.1053/j.gastro.2019.04.016.

Singh N, Bernstein CN. Environmental risk factors for inflammatory bowel disease. United European Gastroenterol J. 2022;10(10):1047-53. doi: 10.1002/ueg2.12319.

Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut. 2011;60(1):49-54. doi: 10.1136/gut.2010.219683.

Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118-32. doi: 10.1053/j.gastro.2021.07.042.

Chen XL, Zhong LH, Wen Y, Liu TW, Li XY, Hou ZK, et al. Inflammatory bowel disease-specific health-related quality of life instruments: a systematic review of measurement properties. Health Qual Life Outcomes. 2017;15(1):177. doi: 10.1186/s12955-017-0753-2.

Brito CAA, Celani LMS, Araújo MVT, Lucena MT, Vasconcelos GBS, Lima GAS, et al. A multicentre study of the clinical and epidemiological profile of inflammatory bowel disease in Northeast Brazil. Clin Exp Gastroenterol. 2023;16:87-99. doi: 10.2147/CEG.S411936.

Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol. 2020;13:1756284820915043. doi: 10.1177/1756284820915043.

Fucilini LMP, Genaro LM, Sousa DCE, Coy CSR, Leal RF, Ayrizono MLS. Epidemiological profile and clinical characteristics of inflammatory bowel diseases in a Brazilian referral center. Arq Gastroenterol. 2021;58(4):483-90. doi: 10.1590/S0004-2803.202100000-87.

Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18(1):56-66. doi: 10.1038/s41575-020-00360-x.

Troelsen FS, Jick S. Antibiotic use in childhood and adolescence and risk of inflammatory bowel disease: a case-control study in the UK Clinical Practice Research Datalink. Inflamm Bowel Dis. 2020;26(3):440-447. doi: 10.1093/ibd/izz137.

Nguyen LH, Örtqvist AK, Cao Y, Simon TG, Roelstraete B, Song M, et al. Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden. Lancet Gastroenterol Hepatol. 2020;5(11):986-95. doi: 10.1016/S2468-1253(20)30267-3.

Zavala-Solares MR, Salazar-Salas L, Yamamoto-Furusho JK. Validity and reliability of the health-related questionnaire IBDQ-32 in Mexican patients with inflammatory bowel disease. Gastroenterol Hepatol. 2021;44(10):711-8. doi: 10.1016/j.gastrohep.2021.03.002.

Quaresma AB, Damiao AOMC, Coy CSR, Magro DO, Hino AAF, Valverde DA, et al. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study. Lancet Reg Health Am. 2022;13:100298. doi: 10.1016/j.lana.2022.100298.

Published

2025-11-10

How to Cite

1.
Andrade E de S, Oliveira CZ, Zardo JM, Santos VV dos. Inflammatory bowel diseases: risk factors and impact on quality of life. Rev. Fac. Ciênc. Méd. Sorocaba [Internet]. 2025Nov.10 [cited 2025Dec.20];27(Fluxo contínuo):e63453. Available from: https://revistas-anterior.pucsp.br/index.php/RFCMS/article/view/63453

Issue

Section

Original Article